VEGF-165 human active recombinant protein
€295.00
In stock
SKU
600176
Protein Family: CAM Ligands, Cytokines
Pathway and Disease: Cancers, Cell Communication, Signal Transduction, Signaling Molecules and Interaction
Alternate Names: Vascular endothelial growth factor a, VEFG-a, vascular permeability factor, VPF, VEFGA, VEGFDescription:
Vascular endothelial growth factor-A (VEGF-A) was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability, it may play a role in stimulating vasolidation via nitric oxide-dependent pathways. Alternative splicing of VEGF-A mRNA results in several isoforms of the protein. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1 , FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Human VEGF-165 produced in E.Coli is a double, non-glycosylated, polypeptide chain containing 165 amino acids with a MW of 38231 Da.
Source: E. coli. Endotoxin level as measured by LAL is <0.01ng/ug or <0.1EU/ug.
Applications: E, WB
Application Notes:
Human recombinant VEGF-165 is fully biologically active when compared to standards. The ED50, as determined by the dose dependent induction of HUVEC proliferation, is 3.2 ng/ml.
Accession No.: P15692
MW: 38231 Da
Sequence:
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
Purity:
Purity > 95% as determined by RP-HPLC and reducing and non-reducing SDS-PAGE. Protein Content determined by UV spectroscopy at 280 nm and analysis by RP-HPLC calibrated against a known standard.
Quantitation on SDS-PAGE against a known standard.
Format:
Each vial contains 10 ug of lyophilized protein. Reconstitute with 0.1 ml sterile deionized water for a final concentration of 0.1 mg/ml.
Storage: Store at -20°C. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C. We recommend to add a carrier protein (0.1% HSA or BSA) for long term storage.
Pathway and Disease: Cancers, Cell Communication, Signal Transduction, Signaling Molecules and Interaction
Alternate Names: Vascular endothelial growth factor a, VEFG-a, vascular permeability factor, VPF, VEFGA, VEGFDescription:
Vascular endothelial growth factor-A (VEGF-A) was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability, it may play a role in stimulating vasolidation via nitric oxide-dependent pathways. Alternative splicing of VEGF-A mRNA results in several isoforms of the protein. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1 , FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF. Recombinant Human VEGF-165 produced in E.Coli is a double, non-glycosylated, polypeptide chain containing 165 amino acids with a MW of 38231 Da.
Source: E. coli. Endotoxin level as measured by LAL is <0.01ng/ug or <0.1EU/ug.
Applications: E, WB
Application Notes:
Human recombinant VEGF-165 is fully biologically active when compared to standards. The ED50, as determined by the dose dependent induction of HUVEC proliferation, is 3.2 ng/ml.
Accession No.: P15692
MW: 38231 Da
Sequence:
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
Purity:
Purity > 95% as determined by RP-HPLC and reducing and non-reducing SDS-PAGE. Protein Content determined by UV spectroscopy at 280 nm and analysis by RP-HPLC calibrated against a known standard.
Quantitation on SDS-PAGE against a known standard.
Format:
Each vial contains 10 ug of lyophilized protein. Reconstitute with 0.1 ml sterile deionized water for a final concentration of 0.1 mg/ml.
Storage: Store at -20°C. Product is guaranteed one year from the date of shipment. Following reconstitution, store at -20°C. We recommend to add a carrier protein (0.1% HSA or BSA) for long term storage.
| Is Featured? | No |
|---|
Write Your Own Review